SCHEMBL17809677

SCHEMBL17809677

CC(=O)Nc1ccc(-c2cc3c(cc2C#N)N(C)CCC3)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 1/20 0.41
FGFR4 P22455 9/20 0.41
BRD4 O60885 1/20 0.40
CREBBP Q92793 1/20 0.40
PRKAB2 O43741 1/20 0.40
PRKAG1 P54619 1/20 0.40
PRKAA2 P54646 1/20 0.40
PRKAA1 Q13131 1/20 0.40
PRKAG3 Q9UGI9 1/20 0.40
PRKAG2 Q9UGJ0 1/20 0.40
PRKAB1 Q9Y478 1/20 0.40
MAPK10 P53779 1/20 0.39
PDE4B Q07343 1/20 0.39
MAPK14 Q16539 1/20 0.39
SYK P43405 1/20 0.39
CSNK2A1 P68400 1/20 0.39
ABL1 P00519 1/20 0.39
TBK1 Q9UHD2 1/20 0.39
TDO2 P48775 1/20 0.39
SCD O00767 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17809792 0.87 CYP11B2 (0.39) CYP11B2FGFR4PRKAB2PRKAG1PRKAA2
SCHEMBL17806320 0.87 FGFR4 (0.40) CYP11B2FGFR4SYKCSNK2A1ABL1
SCHEMBL21254988 0.85 AAK1 (0.40) CYP11B2FGFR4SYKCSNK2A1ABL1
SCHEMBL17809749 0.83 CREBBP (0.47) BRD4CREBBP
SCHEMBL17809596 0.82 CREBBP (0.43) CYP11B2BRD4CREBBPSCD
SCHEMBL17809654 0.82 CYP11B2 (0.41) CYP11B2HPGDCASP1HSD17B10
SCHEMBL17809673 0.82 CYP11B2 (0.41) CYP11B2BRD4CREBBPSYKHPGD
SCHEMBL17809653 0.79 USP30 (0.40) CYP11B2HPGD
SCHEMBL17809669 0.78 RET (0.40) CYP11B2SYKHPGDCASP1HSD17B10
SCHEMBL17809814 0.77 CREBBP (0.48) BRD4CREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3224258-B1 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS GENENTECH INC (US) 2019-08-14 EP disclosed
US-20170333406-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-23 US disclosed
US-9763922-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2017-09-19 US disclosed
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170333406-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 CYP11B2 1605/4885FGFR4 2821/4885BRD4 11/4885
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 CYP11B2 1605/4885FGFR4 2821/4885BRD4 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.